RCM
COEPW

Radcliffe Capital Management’s Coeptis Therapeutics Warrants COEPW Stock Holding History

Radcliffe Capital Management’s Portfolio COEPW Stock Details COEPW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-74,900
Closed -$763K – 694
2020
Q4 		$763K Buy
+74,900
New +$69.1K 0.05% 302

Other funds holding COEPW

CF
Cantor Fitzgerald New York $6.78B AUM 28.97% 1-Year Est. Return
ICM
Ionic Capital Management New York $1.37B AUM 48.26% 1-Year Est. Return
RCM
Rivernorth Capital Management West Palm Beach, Florida $2B AUM 0.79% 1-Year Est. Return
MC
Meteora Capital Boca Raton, Florida $1.36B AUM 20.06% 1-Year Est. Return
CL
CSS LLC Chicago, Illinois $2.09B AUM 58.96% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
Walleye Capital
Walleye Capital New York $28B AUM 44.22% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $6.09B AUM 26.7% 1-Year Est. Return
Walleye Trading
Walleye Trading New York $87.6B AUM 68.17% 1-Year Est. Return
SIA
SkyView Investment Advisors Shrewsbury, New Jersey $743M AUM 17.91% 1-Year Est. Return

Radcliffe Capital Management's COEPW Position: Q3 2023 in Review

Radcliffe Capital Management sold out of Coeptis Therapeutics Warrants (COEPW) in Q3 2023, closing a stake of 70,506 shares — an estimated $5.25K sold.

Radcliffe Capital Management first reported a position in COEPW in Q1 2021 and held it in 10 quarters. The position peaked at $763K in Q3 2022. 19 funds tracked by Wall St. Rank hold COEPW as of Q3 2023.

  • Radcliffe Capital Management reported no remaining Coeptis Therapeutics Warrants position as of Q3 2023 after selling out during the quarter.
  • Radcliffe Capital Management sold 70,506 Coeptis Therapeutics Warrants shares in Q3 2023, an estimated $5.25K.
  • Radcliffe Capital Management first reported a position in Coeptis Therapeutics Warrants in Q1 2021 and held it in 10 quarters.
  • Radcliffe Capital Management's Coeptis Therapeutics Warrants position peaked at $763K in Q3 2022.
  • 19 funds tracked by Wall St. Rank held Coeptis Therapeutics Warrants as of Q3 2023.

Based on Radcliffe Capital Management's 13F filing for Q3 2023, filed 14 Nov 2023.